GlassScriptPhysician profile
John J Alappatt
NPI 1568409688
$4,325.77
in general payments reported to CMS, 2019-2025
15 companies · $174 in 2025
The $174 reported for 2025 was less than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $174 · 2020: $119 · 2021: $510 · 2022: $1,088 · 2023: $894 · 2024: $1,366 · 2025: $174.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,435.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,434.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,108.28 | 2019-2025 | Eylea, Eylea Hd |
| Genentech USA, INC. | $975.08 | 2022-2025 | Vabysmo, Susvimo |
| Notal Vision, INC. | $504.61 | 2022 | |
| Alimera Sciences, INC. | $390.01 | 2019-2024 | Iluvien, Yutiq |
| Astellas Pharma US INC | $293.91 | 2024 | Izervay |
| Apellis Pharmaceuticals, INC. | $273.97 | 2023-2024 | Syfovre |
| Alcon Vision LLC | $167.30 | 2022 | |
| Carl Zeiss Meditec USA, INC. | $166.25 | 2021 | |
| Novartis Pharmaceuticals Corporation | $142.69 | 2019-2020 | |
| Genentech, INC. | $136.91 | 2024 | Vabysmo |
| Optos, INC. | $100.41 | 2021 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Tearlab Corp | $19.21 | 2022 | |
| Abbvie INC. | $14.05 | 2023 | Ozurdex |
| Eyepoint US, INC. | $13.69 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Alappatt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.